Nectar Lifesciences
Nectar Lifesciences Limited is a pharmaceutical company in India that manufactures generic drug products.[1] The company has global leadership in several oral and sterile cephalosporin drugs, and has cGMP facilities along with those approved by the European Union and Japan.[2]
Type | Public |
---|---|
BSE: 532649 NSE: NECLIFE | |
Industry | Pharmaceuticals |
Founded | 1995 |
Headquarters | Chandigarh, India |
Key people |
|
Products | Pharmaceuticals, |
Revenue | ₹ 31.14 billion |
₹ 1.05 billion | |
Number of employees | 2200 |
Website | www |
History
The company was founded by Mr Sanjiv Goyal and was incorporated in June 1995. The company went public in July 2005 with simultaneous listings on the Bombay Stock Exchange and the National Stock Exchange of India. In 2010 New Silk Route Private Equity invested INR 2.5 billion in the company.
Market Cap
The current market capitalization is about INR 578.59 cr.[4]
Products
Nectar Lifesciences manufactures oral and sterile active pharmaceutical ingredients, finished dosages and phytochemicals. The company is also in the business of providing pharmaceutical organizations with contract research and manufacturing services. It also manufactures empty hard gelatin capsules.
References
- "NECTAR LIFESCIENCES LTD (NECLIFE:National Stock Exchange of India): Stock Quote & Company Profile - Businessweek". investing.businessweek.com. Archived from the original on 18 January 2013. Retrieved 28 September 2012.
- "Nectar Lifesciences Limited (Neclife) Receives Anvisa Approval For Its Cephalosporin API's Manufacturing Facility". Institute of Good Manufacturing Practices India. Retrieved 1 July 2018.
- "Stock Quote News - Stock Market Quotes, Online Stock Quotes, India". in.reuters.com. Archived from the original on 4 March 2016. Retrieved 28 September 2012.
- "Nectar Lifesciences". Money Control. Money Control. Retrieved 18 October 2016.